Recommended Adult Immunization Schedule UNITED STATES
for Ages 19 Years or Older
Vaccines in the Adult Immunization Schedule*
2025
Vaccine Abbreviation(s) Trade name(s) How to use the adult immunization schedule
COVID–19 vaccine
1vCOV–mRNA
Comirnaty/Pfizer–BioNTech COVID–19 Vaccine
Spikevax/Moderna COVID–19 Vaccine 1 Determine
recommended
2 Assess need
for additional
3 Review vaccine
types, dosing
4 Review
contraindications
5 Review new
or updated
1vCOV–aPS Novavax COVID–19 Vaccine vaccinations recommended frequencies and and precautions ACIP guidance
by age vaccinations by intervals, and for vaccine types (Addendum)
Haemophilus influenzae type b vaccine Hib ActHIB, Hiberix, PedvaxHIB (Table 1) medical considerations for (Appendix)
Hepatitis A vaccine HepA Havrix, Vaqta condition or special situations
other indication (Notes)
Hepatitis A and hepatitis B vaccine HepA–HepB Twinrix
(Table 2)
Engerix–B, Heplisav–B, PreHevbrio,
Hepatitis B vaccine HepB
Recombivax HB
Human papillomavirus vaccine HPV Gardasil 9
IIV3 Multiple
Report
y Suspected cases of reportable vaccine–preventable diseases or outbreaks to
Influenza vaccine (inactivated, egg-based) aIIV3 Fluad the local or state health department
HD–IIV3 Fluzone High–Dose
y Clinically significant adverse events to the Vaccine Adverse Event Reporting System at
www.vaers.hhs.gov or 800‑822‑7967
Influenza vaccine (inactivated, cell–culture) ccIIV3 Flucelvax
Influenza vaccine (recombinant) RIV3 Flublok
Questions or comments
Contact www.cdc.gov/cdc–info or 800-CDC-INFO (800-232-4636), in English or Spanish,
Influenza vaccine (live, attenuated) LAIV3 FluMist 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.
Measles, mumps, and rubella vaccine MMR M–M–R II, Priorix
Download the CDC Vaccine Schedules app for providers at
MenACWY–CRM Menveo www.cdc.gov/vaccines/hcp/imz-schedules/app.html.
Meningococcal serogroups A, C, W, Y vaccine
MenACWY–TT MenQuadfi
MenB–4C Bexsero Helpful information
Meningococcal serogroup B vaccine y Complete Advisory Committee on Immunization Practices (ACIP) recommendations:
MenB–FHbp Trumenba www.cdc.gov/acip-recs/hcp/vaccine-specific/
MenACWY–TT/ y ACIP Shared Clinical Decision–Making Recommendations:
Meningococcal serogroup A, B, C, W, Y vaccine Penbraya
MenB–FHbp www.cdc.gov/acip/vaccine-recommendations/shared-clinical-decision-making.html
Mpox vaccine Mpox Jynneos y General Best Practice Guidelines for Immunization
www.cdc.gov/vaccines/hcp/imz-best-practices/index.html
PCV15 Vaxneuvance y Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
Pneumococcal conjugate vaccine PCV20 Prevnar 20 y Manual for the Surveillance of Vaccine–Preventable Diseases
PCV21 Capvaxive (including case identification and outbreak response):
www.cdc.gov/surv-manual/php/index.html
Pneumococcal polysaccharide vaccine PPSV23 Pneumovax 23
Poliovirus vaccine (inactivated) IPV Ipol
Respiratory syncytial virus vaccine RSV Abrysvo, Arexvy, mResvia
Tetanus and diphtheria vaccine Td Tenivac Scan QR code
Tetanus, diphtheria, and acellular pertussis for access to
Tdap Adacel, Boostrix online schedule
vaccine
Varicella vaccine VAR Varivax
Zoster vaccine, recombinant RZV Shingrix
*Administer recommended vaccines if vaccination history is incomplete or unknown.
Do not restart or add doses to vaccine series if there are extended intervals between doses.
The use of trade names is for identification purposes only and does not imply endorsement by ACIP or CDC.
, Table 1 Recommended Adult Immunization Schedule by Age Group, United States, 2025
Vaccine 19–26 years 27–49 years 50–64 years ≥65 years
2 or more doses of 2024–2025
COVID–19 1 or more doses of 2024–2025 vaccine (See Notes)
vaccine (See Notes)
Influenza inactivated (IIV3, ccIIV3)
1 dose annually
Influenza recombinant (RIV3)
1 dose annually
(HD–IIV3, RIV3, or aIIV3 preferred)
Influenza inactivated (aIIV3; HD–IIV3)
Solid organ transplant (See Notes)
Influenza recombinant (RIV3)
Influenza live, attenuated
1 dose annually
(LAIV3)
Respiratory syncytial virus 60–74 years
Seasonal administration during pregnancy (See Notes) ≥75 years
(RSV) (See Notes)
Tetanus, diphtheria, pertussis 1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (See Notes)
(Tdap or Td) 1 dose Tdap, then Td or Tdap booster every 10 years
Measles, mumps, rubella 1 or 2 doses depending on indication For health care personnel
(MMR) (if born in 1957 or later) (See Notes)
Varicella 2 doses
2 doses
(VAR) (if born in 1980 or later)
Zoster recombinant
2 doses for immunocompromising conditions (See Notes) 2 doses
(RZV)
Human papillomavirus 2 or 3 doses depending on age at
27–45 years
(HPV) initial vaccination or condition
Pneumococcal See Notes
(PCV15, PCV20, PCV21, PPSV23) See Notes
Hepatitis A
2, 3, or 4 doses depending on vaccine
(HepA)
Hepatitis B
(HepB) 2, 3, or 4 doses depending on vaccine or 2,
condition
3, or 4 doses depending on vaccine or condition
Meningococcal A, C, W, Y
1 or 2 doses depending on indication (See Notes for booster recommendations)
(MenACWY)
Meningococcal B
2 or 3 doses depending on vaccine and indication (See Notes for booster recommendations)
(MenB) 19–23 years
Haemophilus influenzae type b
1 or 3 doses depending on indication
(Hib)
Mpox 2 doses
Inactivated poliovirus
Complete 3-dose series if incompletely vaccinated. Self-report of previous doses acceptable (See Notes)
(IPV)
ecommended vaccination for adults who meet age requirement,
R
lack documentation of vaccination, or lack evidence of immunity Recommended vaccination for adults with an
additional risk factor or another indication Recommended vaccination based on shared
clinical decision–making No Guidance/
Not Applicable
for Ages 19 Years or Older
Vaccines in the Adult Immunization Schedule*
2025
Vaccine Abbreviation(s) Trade name(s) How to use the adult immunization schedule
COVID–19 vaccine
1vCOV–mRNA
Comirnaty/Pfizer–BioNTech COVID–19 Vaccine
Spikevax/Moderna COVID–19 Vaccine 1 Determine
recommended
2 Assess need
for additional
3 Review vaccine
types, dosing
4 Review
contraindications
5 Review new
or updated
1vCOV–aPS Novavax COVID–19 Vaccine vaccinations recommended frequencies and and precautions ACIP guidance
by age vaccinations by intervals, and for vaccine types (Addendum)
Haemophilus influenzae type b vaccine Hib ActHIB, Hiberix, PedvaxHIB (Table 1) medical considerations for (Appendix)
Hepatitis A vaccine HepA Havrix, Vaqta condition or special situations
other indication (Notes)
Hepatitis A and hepatitis B vaccine HepA–HepB Twinrix
(Table 2)
Engerix–B, Heplisav–B, PreHevbrio,
Hepatitis B vaccine HepB
Recombivax HB
Human papillomavirus vaccine HPV Gardasil 9
IIV3 Multiple
Report
y Suspected cases of reportable vaccine–preventable diseases or outbreaks to
Influenza vaccine (inactivated, egg-based) aIIV3 Fluad the local or state health department
HD–IIV3 Fluzone High–Dose
y Clinically significant adverse events to the Vaccine Adverse Event Reporting System at
www.vaers.hhs.gov or 800‑822‑7967
Influenza vaccine (inactivated, cell–culture) ccIIV3 Flucelvax
Influenza vaccine (recombinant) RIV3 Flublok
Questions or comments
Contact www.cdc.gov/cdc–info or 800-CDC-INFO (800-232-4636), in English or Spanish,
Influenza vaccine (live, attenuated) LAIV3 FluMist 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.
Measles, mumps, and rubella vaccine MMR M–M–R II, Priorix
Download the CDC Vaccine Schedules app for providers at
MenACWY–CRM Menveo www.cdc.gov/vaccines/hcp/imz-schedules/app.html.
Meningococcal serogroups A, C, W, Y vaccine
MenACWY–TT MenQuadfi
MenB–4C Bexsero Helpful information
Meningococcal serogroup B vaccine y Complete Advisory Committee on Immunization Practices (ACIP) recommendations:
MenB–FHbp Trumenba www.cdc.gov/acip-recs/hcp/vaccine-specific/
MenACWY–TT/ y ACIP Shared Clinical Decision–Making Recommendations:
Meningococcal serogroup A, B, C, W, Y vaccine Penbraya
MenB–FHbp www.cdc.gov/acip/vaccine-recommendations/shared-clinical-decision-making.html
Mpox vaccine Mpox Jynneos y General Best Practice Guidelines for Immunization
www.cdc.gov/vaccines/hcp/imz-best-practices/index.html
PCV15 Vaxneuvance y Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
Pneumococcal conjugate vaccine PCV20 Prevnar 20 y Manual for the Surveillance of Vaccine–Preventable Diseases
PCV21 Capvaxive (including case identification and outbreak response):
www.cdc.gov/surv-manual/php/index.html
Pneumococcal polysaccharide vaccine PPSV23 Pneumovax 23
Poliovirus vaccine (inactivated) IPV Ipol
Respiratory syncytial virus vaccine RSV Abrysvo, Arexvy, mResvia
Tetanus and diphtheria vaccine Td Tenivac Scan QR code
Tetanus, diphtheria, and acellular pertussis for access to
Tdap Adacel, Boostrix online schedule
vaccine
Varicella vaccine VAR Varivax
Zoster vaccine, recombinant RZV Shingrix
*Administer recommended vaccines if vaccination history is incomplete or unknown.
Do not restart or add doses to vaccine series if there are extended intervals between doses.
The use of trade names is for identification purposes only and does not imply endorsement by ACIP or CDC.
, Table 1 Recommended Adult Immunization Schedule by Age Group, United States, 2025
Vaccine 19–26 years 27–49 years 50–64 years ≥65 years
2 or more doses of 2024–2025
COVID–19 1 or more doses of 2024–2025 vaccine (See Notes)
vaccine (See Notes)
Influenza inactivated (IIV3, ccIIV3)
1 dose annually
Influenza recombinant (RIV3)
1 dose annually
(HD–IIV3, RIV3, or aIIV3 preferred)
Influenza inactivated (aIIV3; HD–IIV3)
Solid organ transplant (See Notes)
Influenza recombinant (RIV3)
Influenza live, attenuated
1 dose annually
(LAIV3)
Respiratory syncytial virus 60–74 years
Seasonal administration during pregnancy (See Notes) ≥75 years
(RSV) (See Notes)
Tetanus, diphtheria, pertussis 1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (See Notes)
(Tdap or Td) 1 dose Tdap, then Td or Tdap booster every 10 years
Measles, mumps, rubella 1 or 2 doses depending on indication For health care personnel
(MMR) (if born in 1957 or later) (See Notes)
Varicella 2 doses
2 doses
(VAR) (if born in 1980 or later)
Zoster recombinant
2 doses for immunocompromising conditions (See Notes) 2 doses
(RZV)
Human papillomavirus 2 or 3 doses depending on age at
27–45 years
(HPV) initial vaccination or condition
Pneumococcal See Notes
(PCV15, PCV20, PCV21, PPSV23) See Notes
Hepatitis A
2, 3, or 4 doses depending on vaccine
(HepA)
Hepatitis B
(HepB) 2, 3, or 4 doses depending on vaccine or 2,
condition
3, or 4 doses depending on vaccine or condition
Meningococcal A, C, W, Y
1 or 2 doses depending on indication (See Notes for booster recommendations)
(MenACWY)
Meningococcal B
2 or 3 doses depending on vaccine and indication (See Notes for booster recommendations)
(MenB) 19–23 years
Haemophilus influenzae type b
1 or 3 doses depending on indication
(Hib)
Mpox 2 doses
Inactivated poliovirus
Complete 3-dose series if incompletely vaccinated. Self-report of previous doses acceptable (See Notes)
(IPV)
ecommended vaccination for adults who meet age requirement,
R
lack documentation of vaccination, or lack evidence of immunity Recommended vaccination for adults with an
additional risk factor or another indication Recommended vaccination based on shared
clinical decision–making No Guidance/
Not Applicable
